Disease · MONDO_0010383
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ZYN002 - Cannabidiol Transdermal Gel vs Placebo Transdermal Gel: deaths from any cause | 0 of 109 | 0 of 102 | 211 | NCT03614663 | Trial comparisons |
| ZYN002 - Cannabidiol Transdermal Gel vs Placebo Transdermal Gel: serious adverse events | 0 of 109 | 0 of 102 | 211 | NCT03614663 | Trial comparisons |
| ZYN002 - Cannabidiol Transdermal Gel vs Placebo Transdermal Gel: Number of Participants With Any Improvement - Clinical Global Impressions- Improvement (CGI-I) - Full Analysis Set | 46 of 109 | 37 of 101 | 210 | NCT03614663 | Trial comparisons |
| ZYN002 - Cannabidiol Transdermal Gel vs Placebo Transdermal Gel: Number of Participants With Any Improvement - Clinical Global Impressions- Improvement (CGI-I) - Ad Hoc Analysis | 43 of 91 | 25 of 76 | 167 | NCT03614663 | Trial comparisons |
| Minocycline vs Placebo: serious adverse events | 0 of 66 | 1 of 66 | 132 | NCT01053156 | Trial comparisons |
| Ganaxolone vs Placebo: deaths from any cause | 0 of 59 | 0 of 54 | 113 | NCT01725152 | Trial comparisons |
| Ganaxolone vs Placebo: serious adverse events | 0 of 59 | 0 of 54 | 113 | NCT01725152 | Trial comparisons |
Placebo Comparator: Double-Blind Placebo With Language Intervention vs Experimental: Double-Blind AFQ056 With Language Intervention: Number of Participants With a Positive Response as Defined by Improvement in Clinical Global Impression - Improvement (CGI-I) Overall Function Scores | 10 of 49 | 8 of 50 | 99 | NCT02920892 | Trial comparisons |
| BPN14770 vs Placebo: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT03569631 | Trial comparisons |
| BPN14770 vs Placebo: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 11 of 30 | 8 of 30 | 60 | NCT03569631 | Trial comparisons |
| BPN14770 vs Placebo: serious adverse events | 1 of 30 | 0 of 30 | 60 | NCT03569631 | Trial comparisons |
| Active vs Placebo: deaths from any cause | 0 of 27 | 0 of 30 | 57 | NCT01474746 | Trial comparisons |
| Active vs Placebo: serious adverse events | 0 of 27 | 0 of 30 | 57 | NCT01474746 | Trial comparisons |
| Donepezil vs Sugar Pill: serious adverse events | 0 of 20 | 0 of 22 | 42 | NCT01120626 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010383/comparisons